Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 30 (2), 866-876

Contrast-enhanced Modified 3D T1-weighted TSE Black-Blood Imaging Can Improve Detection of Infectious and Neoplastic Meningitis

Affiliations

Contrast-enhanced Modified 3D T1-weighted TSE Black-Blood Imaging Can Improve Detection of Infectious and Neoplastic Meningitis

Nora Navina Sommer et al. Eur Radiol.

Abstract

Objectives: To evaluate the diagnostic value of a contrast-enhanced 3D T1-weighted-modified volumetric isotropic turbo spin-echo acquisition sequence (T1-mVISTA) in comparison with a conventional 3D T1-weighted magnetization-prepared rapid gradient-echo (T1-MP-RAGE) sequence for the detection of meningeal enhancement in patients with meningitis.

Methods: Thirty patients (infectious meningitis, n = 12; neoplastic meningitis, n = 18) and 45 matched controls were enrolled in this retrospective case-control study. Sets of randomly selected T1-mVISTA and T1-MP-RAGE images (both with 0.8-mm isotropic resolution) were read separately 4 weeks apart. Image quality, leptomeningeal and dural enhancement, grading of visual contrast enhancement, and diagnostic confidence were compared using the Kruskal-Wallis rank sum test.

Results: Image quality was rated to be good to excellent in 75 out of 75 cases (100%) for T1-mVISTA and 74 out of 75 cases (98.7%) for T1-MP-RAGE. T1-mVISTA detected significantly more patients with leptomeningeal enhancement (p = 0.006) compared with T1-MP-RAGE (86.7 vs. 50.0%, p < 0.001), each with specificity of 100%. Similarly, sensitivity of T1-mVISTA for the detection of dural and/or leptomeningeal enhancement was also significantly higher compared with that of T1-MP-RAGE (96.7 vs. 80.0%, p = 0.025) without significant differences regarding specificity (97.8 vs. 95.6%, p = 0.317). No significant differences were found for dural enhancement alone. Diagnostic confidence in T1-mVISTA was significantly higher (p = 0.01). Visual contrast enhancement was tendentially higher in T1-mVISTA.

Conclusions: T1-mVISTA may be an adequate and probably better alternative to T1-MP-RAGE for detection of leptomeningeal diseases.

Key points: • Black-blood T1-mVISTA showed a significant higher sensitivity for the detection of leptomeningeal enhancement compared with MP-RAGE without losses regarding specificity. • Diagnostic confidence was assessed significantly higher in T1-mVISTA. • T1-mVISTA should be considered a supplement or an alternative to T1-MP-RAGE in patients with suspected leptomeningeal diseases.

Keywords: Magnetic resonance imaging; Meningeal carcinomatosis; Meninges; Meningitis.

Similar articles

See all similar articles

References

    1. AJNR Am J Neuroradiol. 2009 May;30(5):923-9 - PubMed

References

    1. AJR Am J Roentgenol. 2007 Mar;188(3):697-702 - PubMed

References

    1. Neuroimaging Clin N Am. 2012 Nov;22(4):557-83 - PubMed

References

    1. Magn Reson Med. 2010 Mar;63(3):553-61 - PubMed

References

    1. AJNR Am J Neuroradiol. 2018 Aug;39(8):1453-1459 - PubMed

References

    1. Magn Reson Med. 1990 Jul;15(1):152-7 - PubMed

References

    1. N Engl J Med. 2004 Oct 28;351(18):1849-59 - PubMed

References

    1. Br J Radiol. 2017 Jun;90(1074):20160834 - PubMed

References

    1. Ann Oncol. 2017 Jul 1;28(suppl_4):iv84-iv99 - PubMed

References

    1. J Comput Assist Tomogr. 2004 Jan-Feb;28(1):68-72 - PubMed

References

    1. Lancet. 2017 Dec 17;388(10063):3036-3047 - PubMed

References

    1. Lancet Neurol. 2006 May;5(5):443-52 - PubMed

References

    1. AJNR Am J Neuroradiol. 2010 May;31(5):868-73 - PubMed

References

    1. Eur Radiol. 2016 Jun;26(6):1818-25 - PubMed

References

    1. J Comput Assist Tomogr. 1990 Jul-Aug;14(4):536-41 - PubMed

References

    1. Invest Radiol. 2018 Jan;53(1):13-19 - PubMed

References

    1. Intern Med J. 2018 Nov;48(11):1294-1307 - PubMed

References

    1. Radiology. 2000 Oct;217(1):50-3 - PubMed

References

    1. AJNR Am J Neuroradiol. 2002 May;23(5):817-21 - PubMed

References

    1. Lancet. 2012 Nov 10;380(9854):1693-702 - PubMed

References

    1. Lancet. 2012 Nov 10;380(9854):1684-92 - PubMed

References

    1. Clin Neuroradiol. 2016 Jun;26(2):159-67 - PubMed

References

    1. AJR Am J Roentgenol. 1989 Nov;153(5):1039-49 - PubMed

References

    1. Semin Ultrasound CT MR. 2009 Dec;30(6):559-64 - PubMed

References

    1. Acta Radiol. 1997 Jan;38(1):19-24 - PubMed

References

    1. Cancer. 1996 Apr 1;77(7):1315-23 - PubMed

References

    1. AJNR Am J Neuroradiol. 1994 Apr;15(4):633-8 - PubMed

References

    1. AJNR Am J Neuroradiol. 2003 Apr;24(4):719-23 - PubMed

References

    1. Lancet. 2018 Nov 10;392(10159):1789-1858 - PubMed

References

    1. PLoS One. 2016 Oct 3;11(10):e0163081 - PubMed

References

    1. AJNR Am J Neuroradiol. 1986 Nov-Dec;7(6):1013-20 - PubMed

References

    1. AJR Am J Roentgenol. 1994 Jan;162(1):131-5 - PubMed

References

    1. Neuro Oncol. 2017 Apr 1;19(4):484-492 - PubMed

References

    1. Invest Radiol. 2013 Feb;48(2):113-9 - PubMed

References

    1. J Cardiovasc Magn Reson. 2016 Apr 14;18:20 - PubMed

References

    1. Crit Care. 2011;15(3):R136 - PubMed

References

    1. Ther Adv Neurol Disord. 2018 Mar 07;11:1756286418759618 - PubMed

References

    1. Neurology. 1999 Jul 22;53(2):382-5 - PubMed

References

    1. AJR Am J Roentgenol. 1993 Apr;160(4):727-33 - PubMed

References

    1. Radiographics. 2007 Mar-Apr;27(2):525-51 - PubMed

LinkOut - more resources

Feedback